FLEXUS BIOSCIENCES
Flexus is a privately-held biopharmaceutical company focused on the creation, development, and commercialization of novel anti-cancer therapeutics through an innovative application of unexploited insights in immunology. Founded in 2013, Flexus is headquartered in San Carlos, California.
FLEXUS BIOSCIENCES
Social Links:
Industry:
Biopharma Biotechnology Health Care Medical
Founded:
2013-01-01
Address:
San Carlos, California, United States
Country:
United States
Website Url:
http://www.flexusbio.com
Total Employee:
11+
Status:
Active
Contact:
1(650) 489-9000
Email Addresses:
[email protected]
Total Funding:
66.2 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Innodia
Innodia is a privately held biopharmaceutical company with the mission of developing and bringing new drugs.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Founder
Investors List
Kleiner Perkins
Kleiner Perkins investment in Venture Round - Flexus Biosciences
Kleiner Perkins
Kleiner Perkins investment in Series B - Flexus Biosciences
The Column Group
The Column Group investment in Series B - Flexus Biosciences
Celgene
Celgene investment in Series B - Flexus Biosciences
Kleiner Perkins
Kleiner Perkins investment in Series A - Flexus Biosciences
Official Site Inspections
http://www.flexusbio.com
- Host name: 165.89.235.20
- IP address: 165.89.235.20
- Location: Trenton United States
- Latitude: 40.2187
- Longitude: -74.7404
- Metro Code: 504
- Timezone: America/New_York
- Postal: 08629
More informations about "Flexus Biosciences"
Flexus Biosciences - Crunchbase Company Profile
Flexus is a privately-held biopharmaceutical company focused on the creation, development, and commercialization of novel anti-cancer therapeutics through an innovative application of unexploited insights in immunology.See details»
Flexus Biosciences Company Profile 2024: Valuation, …
Flexus Biosciences General Information Description. Developer of small-molecule cancer therapeutics designed to target regulatory T cells. The company is focused on the creation, development and commercialization of novel anti …See details»
Flexus Biosciences - LinkedIn
Flexus Biosciences | 225 followers on LinkedIn. Bristol-Myers Squibb acquired Flexus for $800M upfront & $450M in potential earnouts in 2015. | Founded in 2013, Flexus is a privately-held ...See details»
Flexus Biosciences - Ownership and Business Overview - Mergr
United States, www.flexusbio.com. Profile Investors (1) Analytics Flexus is a biotechnology company focused on the discovery, development, and commercialization of small-molecule …See details»
Flexus Biosciences, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Flexus Biosciences, Inc. of San Carlos, CA. Get the latest business insights from Dun & Bradstreet.See details»
Flexus Biosciences Inc - Company Profile and News
Company profile page for Flexus Biosciences Inc including stock price, company news, executives, board members, and contact informationSee details»
Flexus Biosciences, Inc. - Drug pipelines, Patents, Clinical trials ...
Explore Flexus Biosciences, Inc. with its drug pipeline, therapeutic area, technology platform, .See details»
Flexus Biosciences - Crustdata Company Profile, Funding and Growth
Flexus is a privately-held biopharmaceutical company focused on the creation, development, and commercialization of novel anti-cancer therapeutics through an innovative application of …See details»
Bristol-Myers Squibb To Expand Its Immuno-Oncology Pipeline …
“Bristol Myers Squibb is a recognized leader in the cancer immunotherapy field, and we are delighted with the opportunity to have their organization advance the development of our …See details»
Flexus Biosciences - Products, Competitors, Financials, Employees ...
Headquarters Location. 75 Shoreway Road Suite D. San Carlos, California, 94070, United States. 650-489-9000See details»
BMS to acquire biotechnology firm Flexus for $1.25bn
Feb 23, 2015 Flexus Biosciences CEO Terry Rosen said: "Bristol Myers Squibb is a recognised leader in the cancer immunotherapy field, and we are delighted with the opportunity to have …See details»
Flexus Bioscience | CipherBio
Explore Flexus Bioscience's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
Bristol Myers Squibb - Bristol-Myers Squibb Completes Previously ...
Apr 8, 2015 Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has completed the previously announced planned acquisition of Flexus Biosciences, Inc. The …See details»
Bristol-Myers Squibb To Expand Its Immuno-Oncology Pipeline …
Feb 23, 2015 Gains full rights to Flexus’ lead preclinical IDO1 inhibitor F001287 and the company’s broad IDO/TDO discovery program; Enables Bristol-Myers Squibb to fully explore …See details»
Flexus Biosciences Chemists Spin Off New Company After
April 6, 2015 By Mark Terry, BioSpace.com Breaking News Staff After San Carlos, Calif.-based Flexus Biosciences was bought by New York’s Bristol-Myers Squibb Company for $1.25 billion …See details»
Bristol-Myers Squibb To Expand Its Immuno-Oncology Pipeline …
Feb 23, 2015 "Bristol Myers Squibb is a recognized leader in the cancer immunotherapy field, and we are delighted with the opportunity to have their organization advance the development …See details»
Bristol Myers Squibb : To Expand Its Immuno-Oncology Pipeline …
Feb 23, 2015 8d0574a446033.zLsst30XY0EDI3bhk__EV6b9zYS-VXNFM525dHE4kxI.leoB-zpHICtKZg6g6rOGL_GsndLhPAJ9bMvQHilT9HP97EnfEk9UCnlsOwSee details»
BMS acquires biotechnology firm Flexus Biosciences for $1.25bn
Apr 9, 2015 Bristol-Myers Squibb (BMS) has completed the acquisition of biotechnology firm Flexus Biosciences for around $1.25bn.. Under the deal, Flexus has received an upfront …See details»
Working at Flexus Biosciences - Glassdoor
The acquisition will give Bristol-Myers Squibb full rights to F001287, Flexus’ lead preclinical small molecule IDO1-inhibitor targeted for IND filing in the second half of 2015.See details»